From 2D to organ-on-a-chip: Platforms powering modern disease models

8 Apr 2026

Over the past decade, disease models have advanced rapidly, providing new ways to study human biology with greater accuracy and relevance. While animal models once dominated, the field now draws on a broader, more sophisticated toolkit that includes 2D cell cultures, 3D organoids, and organ-on-a-chip. Each platform offers unique advantages and limitations, and together they are reshaping a new era of disease modeling in the laboratory.

This transformation is driven by scientific innovation and regulatory momentum. Recent developments, including the U.S. FDA’s 2025 easing of requirements for animal testing,¹ along with growing patient demand for more ethical and predictive models, are influencing research priorities. The key question is no longer whether to move beyond animal models, but which platform best fits the needs of a study.

2D cell cultures: Scalable tools for early-stage research

2D cell cultures have long formed the backbone of biomedical research, where cells are grown as a flat monolayer on culture dishes or plates, creating a controlled environment for experiments.² Their simplicity provides high reproducibility, standardized protocols, and cost-effective, high-throughput screening, ideal for early-stage studies and mechanistic investigations.

However, flat monolayers cannot capture the complex architecture, cell–cell interactions, or mechanical cues present in living tissues. Consequently, findings that appear promising often fail to translate to animal models or clinical settings. Despite these limitations, 2D systems remain indispensable when reproducibility and scale are priorities.

Organoids: Patient-specific models with 3D complexity

Organoids represent a significant advancement in disease modeling. Derived from induced pluripotent stem cells (iPSCs), they self-organize into structures that closely mimic the architecture and function of tissue.³ This patient-specific modeling enables more personalized investigations into disease mechanisms and potential therapies.

Tumor organoids, for example, can replicate an individual’s genetic profile and drug response, offering a pathway to precision oncology. Brain organoids are increasingly used to model developmental disorders and neurodegeneration in ways that were previously impossible.

Despite their promise, challenges remain, including batch-to-batch variability and the absence of vasculature or immune components, which can limit physiological accuracy.⁴ Efforts to establish quality control standards and reproducibility frameworks are underway.⁵ To support these advances, FUJIFILM Biosciences provides resources such as the differentiation poster, which charts the journey from stem cell to organoid and offers practical tools to strengthen reproducibility in organoid workflows.

Organ-on-a-chip: Dynamic platforms for human physiology

Organ-on-a-chip provide a highly advanced platform for modeling tissue function under physiologically relevant conditions.⁶ These micro-engineered devices combine living cells with fluid flow and mechanical forces, mimicking the microenvironment of human organs. Dynamic processes such as absorption, distribution, and toxicity are captured more accurately than in static cultures.

Multi-organ platforms further expand these capabilities, creating interconnected tissue models that simulate systemic responses to drugs or disease. These systems often predict human-specific drug responses more effectively than traditional animal models, particularly in toxicology and pharmacokinetics.⁷

Despite their potential, organ-on-a-chip can be challenging to design and operate, and their success relies on the use of high-quality input cells and reagents.

Integrating platforms towards standardized, Reproducible models

No single platform addresses all aspects of disease modeling. 2D cultures, organoids, and organ-on-a-chip each bring complementary strengths. Hybrid approaches allow data from one platform to inform experiments in another, enhancing predictive accuracy and reducing reliance on animal models.

Organoids and chip-based platforms are merging to create more physiologically relevant hybrid systems. Organoids-on-a-chip combine 3D cellular complexity with microfluidics, enabling vascularized organoids and interconnected tissue models that capture systemic biology.⁸ These approaches expand functional readouts from drug response to multi-organ interactions, while preserving the advantages of each platform.

As the field evolves, it’s crucial to balance innovation with reproducibility and standardization. To support this, FUJIFILM Biosciences provides reagents, tools, and quality frameworks that strengthen workflows across 2D, organoid, and chip-based systems. Fuijfilm's disease modeling page serves as a central resource for exploring these solutions and integrating them into research.

Looking ahead: Driving predictive and ethical disease models

The progression from 2D cultures to organoids, organ-on-a-chip, and hybrid platforms has expanded the possibilities for modeling human disease. Scientific advances, regulatory shifts, and demand for predictive, ethical systems continue to shape the field, emphasizing the need for models that balance accuracy, scalability, and physiological relevance.